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Available online 20 August 2016Early screens for new diabetes drugs rely onmonolayers of β-cells, which are known to be poor predictors of the
in vivo response. Previously, we developed a method to create uniform islet spheroids from freshly-dispersed
human donor tissue for drug screening. While the human engineered islets worked well to reduce donor-to-
donor variability, it is difﬁcult and expensive to obtain sufﬁcient high-quality human islets for drug testing.
Thus, this study utilized a genetically-modiﬁed β-cell culture line (INS-1832/13) in 2D and as 3D spheroids
and compared the results to human islet tissue formed into spheroids using a high-throughput 384-well format.
In response to increasing concentrations of glucose, all 3 groups increased insulin release, but the culturedβ-cells
(2D and 3D) were more sensitive to glucose (EC50 5.85 mM for 2D β-cells, 16.24 mM for 3D β-cell spheroids)
than the human islet spheroids (EC50 53.69mM). The order of responses to glybenclamidewas human spheroids
N3D β-cell culture N2D β-cell culture. In response to caffeine, the β-cells in 2D or 3Dweremore responsive com-
pared to thehuman islet spheroids (EC50 0.39 and 0.31mMfor 2Dand 3Dβ-cells respectively).When exposed to
inhibitors of insulin secretion (nifedipine and diazoxide), the responses were more similar between groups. Z'
calculations, indicative of assay quality, determined that the 3D β-cell spheroids reached the criteria of an excel-
lent to ideal drug screen assay more consistently than the other test models. In conclusion, 3D β-cell spheroids
from a cultured cell line can be used in HTS assays that, according to reference drugs tested here, are sensitive
and predictive of the in vivo response.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Nifedipine1. Introduction
The United States, along with other growing countries such as India
and China, have been affected by a dramatically increasingprevalence of
diabetes. Today, the etiology of both type 1 and type 2 diabetes is
thought to revolve around the dysfunction of β-cells, the insulin pro-
ducing cells of the body (Law, Ashcroft, Zheng, & Sexton, 2014) (Lupi
& Del Prato, 2008). When β-cells are attacked either by chronic inﬂam-
mation or autoimmunity, the loss of insulin production leads to in-
creased blood glucose levels and eventually a diagnosis of diabetes.
Thus, even in cases of undiagnosed diabetes, reduction in the β-cell
count or impaired β-cell function are present (Ferrannini & Mari,
2014; Watkins, Evans-Molina, Blum, & DiMeglio, 2014).
Within the pharmaceutical industry, secondary testing of new po-
tential compounds for diabetes often relies on assays aimed atl Center, Department of Physical
, Kansas City, KS 66160, United
. This is an open access article undermeasuring an impact on insulin secretion and often uses of β-cell
insulinoma cell lines and rodent islets (Walpita & Wagner, 2014). Ro-
dent islets are not physiologically or morphologically similar to
human islets (Ramachandran, Huang, & Stehno-Bittel, 2014), thus
they are poor predictors of medicinal outcomes in humans. This lack
of predictability has been cited as one of the reasons for the excessive
expense associated with bringing a new drug to market (DiMasi,
Grabowski, & Hansen, 2014).
For the testing of new diabetes drugs, β-cell culture lines are created
from transformed human or rat pancreatic β-cells. Grown in standard
monolayers, these cell lines secrete insulin in response to some com-
pounds (Burns et al., 2015), but in general are poor predictors of how
the human body will respond to the compound in vivo (Rupnik, 2009;
Wikstrom et al., 2012). The exception may be the adapted insulinoma
cell line, INS-1 832/13, a β-cell line that has been shown to respond
well to increasing glucose concentrations (Hohmeier & Newgard,
2004), with a rapid increase in ATP/ADP and malonyl CoA activity
(Lorenz, El Azzouny, Kennedy, & Burant, 2013). In addition, INS-1 832/
13 cells show signs of forming aggregates of ubiquitinated proteins in
response to high glucose – something noted in the intact pancreasthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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most physiologically relevant β-cell models available (Hectors,
Vanparys, Pereira-Fernandes, Martens, & Blust, 2013). Importantly,
these cells can maintain a differentiated phenotype for 6 months in cul-
ture (Hohmeier et al., 2000), and the cells have been used in screening
environmental pollutants that could impact β-cell function (Hectors et
al., 2013; Hohmeier et al., 1997). To date, there have been no published
studies using the INS-1 832/13 β-cell culture line to create 3D spheroids
for drug screening in the high-throughput format.
Previously, we developed and tested a simple method for the crea-
tion of 3D spheroids that did not require scaffolds, gels or 3D printers.
Rather, the procedure builds on the inherent self-aggregatingproperties
of most cells (Ramachandran, Williams, Huang, Novikova, & Stehno-
Bittel, 2013). Created in micromolds, the process can create 200,000
uniform spheroids in a standard cell culture plate. Later, we illustrated
the ability of 3D reaggregated human islet spheroids, which we call
Kanslets, to respond to known insulin secretagogues and insulin secre-
tion inhibitors in a manner that was similar to the in vivo response
(Ramachandran et al., 2014).We showed that they were superior to in-
tact human islets in drug screens using reference compounds. However,
creating the human islet spheroids still required donor islet tissue,
which is expensive to obtain and there is often not enough healthy tis-
sue present to run large-scale compound screens.
The purpose of this study was to determine whether the same reag-
gregation process could be used to form 3D β-cell spheroids from a cul-
tured cell line and to compare the results with the same cells in 2D and
with reaggregated human islets. In addition, the procedure was modi-
ﬁed for the high-throughput 384-well format. Reference drugs with
known in vivo insulin secretion or insulin inhibition responses were
tested on the 3 cell models.2. Methods and materials
2.1. Cell culture
The INS-1 832/13 cell line is a derivation of the INS-1 cell line and was
graciously provided by the Sarah W. Stedman Nutrition and Metabolism
Center, Duke University, Durham, NC. Cells were cultured in a growth
medium consisting of RPMI-1640, along with 1 M HEPES buffer solution,
50× INS supplement (glutamine, Na-pyruvate, and B-mercaptoethanol),
Antibiotic-Antimycotic (Gibco by LifeTechnologies), and Fetal Bovine
Serum (HyClone). Cells were grown and sustained in a T75 cell culture
ﬂask. The cells were placed in a humidiﬁed incubator at 37 °C and 5%
CO2. Due to the rapid growth of these cells, media was changed on every
second day and passaged on every fourth day via trypsinization. At
passage, one-fourth of the cells was moved to a T75 ﬂask with the
remainder of the cells placed in a micro-mold to allow the creation of
uniform, islet spheroids. For this study, cells with the population
doubling (PD) of 53-93 were used.2.2. Formation of β-cell aggregates
Custom micromolds were used to create uniform, β-cell spheroids
with a maximum diameter of b100 μm (Ramachandran et al., 2014).
Cells were loaded into the micromold at a density of approximately 1
million/ml medium. Medium was change daily by partial replacement.
Cell aggregates were allowed to form in the micromold for 72 h and
then were transferred to a 100 mm non-treated tissue culture dish for
an additional 48 h prior to exposure to the test drug. Spheroids were
passed through 70 μm and 100 μm cell strainers (#3431751 and
#43152, Corning, Tewksbury, MA) and maintained in HEPES Balanced
Salt Solution comprised of: 20 mM HEPES, 114 mM NaCl, 4.7 mM
KCl,1.2 mM KH2PO4,1.16 mMMgSO4, 2.5 mM CaCl2, 25.5 mM NaHCO3
and 0.2% bovine serum albumin (fatty acid free), pH 7.2.2.3. Human Kanslet formation
Human islets from9 adult donorswere obtained from the Integrated
Islet Distribution Program (IIDP). Isolated islets were maintained in
CMRL 1066 medium with 2 mM L-glutamine, 10% FBS and 1% antibiot-
ic/antimycotic at 37 °C in a culture chamber containing 5% CO2. Islets
were dispersed as described previously by digestion in cmf-HBSS sup-
plemented with papain (10 units/ml; Worthington, Lakewood, NJ) fol-
lowing washing in media free of calcium and magnesium
(Ramachandran et al., 2014). Suspensions were incubated on a rotator
at 37 °C for 10–15 min, and manually dispersed with a pipette until
the cell suspension primarily contained single cells. The cells were
then washed to remove residual papain and transferred to an aggregate
culture medium, consisting of CMRL 1066 supplemented with 2 mM L-
glutamine, 10% FBS and 100 U penicillin, 100 μg streptomycin, and 25 μg
amphotericin.
The single cell suspension was then plated onto sterile glass
micromolds using the same protocol described above for the cultured
β-cells. Cells in the micromolds were incubated for 3–5 days at 37 °C
and 5% CO2. Cells reaggregated while limiting the size to no bigger
than the recess allowed (100 μm). Aggregate culture medium was
changed every 24 to 48 h until reaggregated islets were formed.
Reaggregated islet clusters (Kanslets) were removed by washing the
micromold several times with culture medium until they were
dislodged and were aspirated with a pipette to be plated in CMRL-
based medium for long-term culture. Brightﬁeld images of the spher-
oids forming in the micromold and after removal were captured on an
inverted Nikon microscope, Olympus Fluoview Confocal Microscope,
using a 20× objective.2.4. Compound testing
To test the glucose- or compound-stimulated insulin secretion or in-
hibition, cells in the 3 test conditions (2Dβ-cell culture, 3Dβ-cell spher-
oids or human Kanslets) were reconstituted in 1× EBSS supplemented
with 0.1% BSA and low (2.8 mM) glucose and dispersed into 384-well
plates. The average loading cell density for the 2D screens was 5 × 103
cells/well in the 382-well plates and approximately 2 × 104 cells/well
in the pilot studies conducted in 96-well plates. To verify loading densi-
ty, images of each well were captured. Experiments were run in repli-
cates of quadruplicates, with each dose response relationship tested
independently 3 times.
Each well was subjected to a 60-minute static incubation at 37 °C
and 5% CO2 in EBSS containing varying doses of glucose and/or test com-
pounds. Compounds, prepared in EBSS, were added to each well to
achieve desired compound dose and a ﬁnal concentration of 11.2 mM
glucose (unless otherwise noted) using procedures we have published
previously (Ramachandran et al., 2014). Optimization of each test con-
dition (2D, 3D or human Kanslets) led to the determination that ideal
results were obtained with approximately 30 spheroids/well.
After the 60min incubationwith test compounds, the secreted insu-
lin was tested via Alpha-LISA test system (Perkin Elmer). Brieﬂy, a two-
stage approach was utilized, which involved adding acceptor solution
(acceptor beads, antibody and buffer) to the spheroids initially and
15 min later adding the donor solution (donor beads and buffer). The
signal was read on an EnSpire Mulitmode Plate Reader (Perkin Elmer)
with excitation 680 nm and emission measured at 615 nm. Values
were converted to insulin concentration, and dose/response curves
were determined for each single assay and single-run assay quality
was assigned based on the signal window. Values of blank wells
(media, with vehicle where appropriate) were subtracted from each
well, and insulin concentration values were normalized by dividing by
the 0 drug wells (media + cells). Further quality assurance was deter-
mined by calculating the signal-to-noise ratio (S/N) and Z' values
using equations provided in the results section.
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were conducted using standard ELISA procedures. After incubationwith
the test compound, the conditionedmediumwas collected and kept fro-
zen at −80 °C for later determination of insulin content by ELISA.
Human insulinwas detected using the human ELISA kit (Mercodia Upp-
sala, Sweden) and rat insulin was detected with the rat version (APLCO,
#80-INSRTH-E01, Salem, NH).2.5. Assay quality
Assay qualitywas assigned based on the signalwindowas deﬁned in
NIH's Assay Guidance Manual (Iversen et al., 2004). The signal-to-noise
(S/N) calculation takes into consideration the amplitude of the test re-
sponse over the background. Each plate used in an assay included a pos-
itive control, designed to elicit a maximal insulin secretion from the
sample. In this study, the positive control consisted of a depolarizing so-
lution in high glucose (35 mM K+ in 22 mM glucose). The S/N was cal-
culated as:
S=N ¼ mean signal−mean backgroundð Þ
=standard deviation of background
Z' is another quality assurancemeasure, which has been shown to lower
the inﬂuence of outliers (Gubler, 2006). The robustness of each re-
sponse was determined based on the Z' following the procedures
outlined by Zhang, Chung, and Oldenburg (1999).
Z0 ¼ 1−½ 3  control standard deviationþ 3  sample standard deviationð Þ
= control meanþ sample meanð ÞFig. 1. Formation of 3D spheroids. A) A representative picture of the divots within the mold con
mold shows mature spheroids in every divot. Scale bar = 50 μm. C) β-cell spheroids were re
produced from D) human islet cells, Kanslets. Scale bar for both = 100 μm.2.6. Statistics
One-way ANOVA was used to compare different doses within the
same experiment with post-hoc Tukey test when necessary. P b 0.05
was deﬁned as statistically signiﬁcant.
3. Results
3.1. Formation of 3D β-cell spheroids
INS-1 832/13 cells were loaded into the micromold at a density of
approximately 1million cells/ml. Fig. 1A shows a representative picture
of the divots within the mold containing 15–30 cells/divot only 20 min
after seeding. 3 days later, the same mold shows clearly delineated
spheroids in every divot (Fig. 1B). At that time, spheroidswere removed
from the micromold as shown in Fig. 1C and washed. The β-cell spher-
oids had the same general appearance and size as the spheroids pro-
duced from human islet cells, Kanslets (Fig. 1D). The average diameter of
the β-cell spheroids at the time of removal from the micromold was
70 μm, but cells continued to replicate after removal from the mold. At
the time of drug testing, the β-cell spheroids were between 70 and
150 μm in diameter. Kanslet spheroids were under 80 μm in diameter.
3.2. Insulin-secretion stimulation: glucose stimulation
The response of isolated islets to increasing doses of glucose is a hall-
mark of healthy β-cell function, and is commonly used as a pre-screen-
ing test on freshly isolated tissues. β-cells cultured into 3D spheroids or
in a 2Dmonolayer andhumanKansletswere each exposed to increasing
doses of glucose from 1.4 to 33.6 mM for 60 min. This range of glucose
concentrations is the equivalent of 25 to 660 mg/dl, thus covering an
equivalent physiological range of severe hypoglycemia to extremetaining 15–30 cells/divot 20 min after seeding. Scale bar = 50 μm. B) 72 h later, the same
moved from the micromold had the same general appearance and size as the spheroids
Fig. 2.Glucose-stimulated insulin secretion.HumanKanslets alongwithβ-cells cultured in
2Dor as 3D spheroidswere exposed to increasing doses of glucose from1.4 to 33.6mM for
60min. All 3 groups responded appropriately to the increasing concentration of glucose by
releasing more insulin, but the human Kanslets were the least sensitive. N= 9 trials, 4
repetitions each for human Kanslets and 3 trials each for β-cell groups. ⁎indicates
statistically different values, p b 0.001.
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concentration of glucose by releasing more insulin (Fig. 2). Speciﬁcally,
the human Kanslets were the least sensitive to glucose requiring expo-
sure to 28mMglucose before a statisticallymeasurable increase in insu-
lin concentrationwasmeasured (minimal detectible dose, Table 1). The
β-cell spheroids had aminimal detectible dose of 16.8mMglucose with
an estimated EC50 of 16.24mMglucose. In contrast, the 2Dmonolayer of
β-cells demonstrated the greatest sensitivity to the glucose with the
lowest dose necessary to identify a statistically signiﬁcant increase of
basal conditions and the lowest EC50 value (Table 1). The slopes of the
3 responses were quite different with the steepest slope found in the
2D culture followed by the 3D β-cell spheroids and Kanslets (Table 1).
The stimulation index (SI) is the percent increase in insulin secretion
when comparing the highest glucose concentration to the lowest. For
the 3 conditions in 33.6 mM glucose, the mean SI values were 4.50 for
2D cell culture, 4.31 for 3D β-cell spheroids, and 1.94 for humanTable 1
Quality assurance values for assays.
For each test compound utilized in the study the concentration at which the response was stat
signiﬁes the dose at which a high-throughput screen would be able to detect a difference. The
pound. The Z' value indicates the quality of the assay alongwith the robustness of the response t
near or at 1 classiﬁed as an ideal assay. The humanKanslets failed to demonstrate a Z' value in th
value in the excellent range in response to caffeine only. In contrast, the 3D β-cell model ran
glybenclamide.
Agonist/antagonist Cell model Minimal detectib
Glucose (mM) 2D β-cell culture 5.60
β-Cell spheroids 16.80
Human Kanslets 28.00
Glybenclamide (nM) 2D β-cell culture na
β-Cell spheroids 10.00
Human Kanslets 1.00
Caffeine (mM) 2D β-cell culture 0.30
β-Cell spheroids 0.30
Human Kanslets 10.00
Nifedipine (μM) 2D β-cell culture 0.03
β-Cell spheroids 0.10
Human Kanslets 0.03
Diazoxide (μM) 2D β-cell culture 30.00
β-Cell spheroids 10.00
Human Kanslets 30.00
⁎ Indicates a statistically signiﬁcant difference between the 2D β-cell culture and human Ka
# Indicates a statistically signiﬁcant difference between the 2D β-cell culture and 3D β-cell s
@ Indicates a statistically signiﬁcant difference between 3D b-cell spheroids and human KanKanslets. The SI values for the 2D and 3D β-cells were not statistically
different from each other, but the value for the humanKansletswas sta-
tistically lower than the other 2 groups.3.3. Insulin secretogogues: glybenclamide
Glybenclamide is an anti-diabetic drug that belongs to the sulfonyl-
urea class. Its primarymechanismof action is to block theATP-regulated
potassium channel and induce and/or stimulate electrical activity in the
β-cell, which in turn enhances insulin secretion (Garcia-Barrado, Jonas,
Gilon, & Henquin, 1996). At 1 μM glybenclamide, islets were shown to
have an enhanced response to 15 mM glucose, thus a range of concen-
trations at and below 1 μM were tested (Garcia-Barrado et al., 1996).
The human Kanslets secreted more insulin with increasing doses of
glybenclamide, indicating that it was more efﬁcacious on the Kanslets
than either of the β-cell models (Fig. 3). In fact, all values of insulin se-
cretion from the Kanslets were statistically greater than the 0 drug
level. Conversely, there was no statistical increase in insulin secretion
in the 2D cultured β-cells compared to the basal (0 drug) condition
(Table 1). The 3D β-cell spheroids showed an increase in insulin secre-
tion. While the minimal statistically detectible concentration was
10 nM, an EC50 value could not be calculated within the doses shown
in Fig. 3. Additional experiments that included higher concentrations
of glybenclamide resulted in an EC50 value of 384 nM.3.4. Caffeine
Caffeine acts to increase intracellular Ca2+ by inducing release
through the Ca2+ channels of the endoplasmic reticulum, bypassing
plasmamembrane receptor binding and subsequent secondmessenger
signaling. The Ca2+ transient is a required step in the pathway fromglu-
cose stimulation to exocytosis of the insulin-containing granules. Fig. 4
summarizes the results of all three cell models responding well to caf-
feine concentrations previously shown to increase insulin secretion
(Ramachandran et al., 2014). The 2D β-cell culture and the 3D β-cell
spheroids had nearly identical values for the minimal detectible dose
and EC50 (Table 1). In contrast, only the highest dose of caffeine resulted
in a statistically increased amount of released insulin in the Kanslet
group, due to high variability. The Hill slope calculated from the dose/istically different from baseline (0 drug value) was called the minimal detectible dose and
EC or IC50 and the Hill slope provide some information regarding the potency of the com-
o the compound. A Z' value between 0.5 and 1 is considered an excellent assay,with values
e excellent or ideal range for any of the experiments run. The 2D cell culturemodel had a Z'
ked in the excellent range for every experiment except when stimulated by glucose and
le dose EC or IC50 Hill slope Z'
5.85 31.66⁎,# −3.95
16.24 5.15 0.11
53.69⁎ 2.12 −0.25
na na −1.86
384.00 0.43 0.48
12.05# 1.46 0.16
0.39 0.61 0.66
0.31 0.97 0.65
na 0.78 0.23
0.06 −0.26 0.01
0.14 −0.66@ 0.53
0.03 −14.39 −3.12
7.69 −0.23 0.07
2.44 −1.74 0.72
8.09 −0.94 −0.49
nslets at p b 0.05.
pheroids at p b 0.05.
slets at p b 0.05.
Fig. 3. Glybenclamide-stimulated insulin secretion. β-cells cultured in 2D or as 3D
spheroids along with 3D human Kanslets were exposed to increasing doses of
glybenclamide from 1 to 1000 nM for a 60 min static incubation at 37 °C and 5% CO2 in
EBSS. The human Kanslets secreted statistically more insulin with each increasing dose
of glybenclamide (# indicates p b 0.01). Likewise, the 3D β-cell spheroids showed an
increase in insulin secretion. There was no statistical increase in insulin secretion in the
2D cultured β-cells compared to baseline. N = 3 trials, 4 repetitions each. ⁎indicates
statistically different values between the 2D cell culture and the other groups, p b 0.005.
Fig. 5. Nifedipine-induced insulin secretion inhibition. A1 h exposure to nifedipine
resulted in a graded decrease in insulin secretion from all 3 groups. The 3D β-cell
spheroids showed the strongest level of inhibition with nifedipine concentrations of
3 μM and higher. The IC50 for nifedipine was between 0.03 and 0.14 for the 3 groups.
⁎indicates statistical signiﬁcance at only the highest dose for the 3D β-cell spheroids and
compared to the human Kanslets at p b 0.05. Results are average of 3 independent trials
(4 repetitions at each dose).
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monolayer β-cells were lower (Table 1).
3.5. Insulin secretion inhibitors: calcium channel blockers
Calcium inﬂux during action potentials is essential for the triggering
of exocytosis and the subsequent insulin release (Pento, Kagan, & Glick,
1974). Blocking inﬂux through cell surface voltage-dependent Ca2+
channels is a non-selectiveway to reduce insulin secretion at stimulato-
ry glucose levels (Al-Mahmood, el-Khatim, Gumaa, & Thulesius, 1986).
The voltage-dependent Ca2+ channel blocker, nifedipine, was tested
in a dose range shown previously to inhibit the normal Ca2+ transient
in response to 28 mM glucose (Qureshi, Dejene, Corbin, & Nunemaker,
2015). Exposure to increasing concentrations of nifedipine resulted in
a graded decrease in insulin secretion from all 3 groups (Fig. 5). The
IC50 for nifedipine was between 0.03 and 0.14 for the 3 groups withFig. 4. Caffeine-stimulated insulin secretion. All cell models were exposed to increasing
doses of caffeine from 0.01 to 10 mM for a 60 min static incubation (4 reps at each dose,
3 separate trials). The cells responded well to caffeine exposures of 300 μM and above.
The 2D β-cell culture and the 3D β-cell spheroids had identical values for the minimal
detectible dose and the EC50 were similar. In contrast, only the highest dose of caffeine
resulted in a statistically increased amount of released insulin in the Kanslet group. Only
the 2D and 3D β-cell models were statistically different from each other at the highest
dose tested (p b 0.05).minimal detectible differences that were similar between groups
(Table 1). The 3D β-cell spheroids showed the strongest level of inhibi-
tion with higher doses of nifedipine compared to the other two groups.
3.6. ATP-dependent K+ channel (KATP) activators
Diazoxide was introduced into clinical use as an anti-hypertension
medication that was later shown to inhibit insulin secretion by directly
activating KATP channels and altering mitochondrial function, subse-
quently causes the inhibition of insulin release (Grimmsmann &
Rustenbeck, 1998; Jijakli et al., 1996; Wajchenberg, 2007). All three
groups tested responded appropriately to diazoxide at doses from 0.3
to 300 μM (Fig. 6). This dose range was chosen because it coincides
with the standard test range for diazoxide for cultured beta cells
(Zhang et al., 2013). However, the 3D spheroids and the Kanslets were
the least effective with approximately a 60% reduction in insulin secre-
tion at the highest dose (300 μM), while the 2Dmonolayer demonstrat-
ed an almost complete loss of insulin release. The calculated IC50
values were very close for all three groups, between 2.44 and 8.09 μM
(Table 1). Likewise, the Hill slopes were similar.Fig. 6. Diazoxide-induced insulin secretion inhibition. All three groups tested responded
appropriately to inhibition by diazoxide at concentrations of 0.3 to 300 μM. However,
the 3D spheroids and the Kanslets were the least responsive, while the 2D monolayer
demonstrated an almost complete loss of insulin release at 100 μM diazoxide. There
were no statistically signiﬁcant differences in the 3 models tested.
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In order to quickly determine whether a test compound deserves
further study based on a single large-assay screen, the quality of the
screen must be exceptional. Several classical assay analysis methods
have been identiﬁed and used in the pharmaceutical industry. The sig-
nal-to-noise calculation takes into consideration the amplitude of the
test response over the background, but it also includes calculations for
the standard deviation of the background. Cut points for S/N values
are dependent on the assay type and are not widely published, but
any value below 2 does not provide enough distinction to determine
drug efﬁcacy.
Each plate used in an assay included a positive control, designed to
elicit amaximal insulin secretion from the sample. In this study, thepos-
itive control consisted of a depolarizing solution in high glucose (35mM
K+ in 22 mM glucose). The signal-to-noise ratio of the depolarization
signal when applied to 2D β-cells was quite high (27.60), and is consis-
tentwith the high sensitivity that the 2D cell culturemodel demonstrat-
ed to increased glucose concentrations in Fig. 2. Microplates with β-cell
spheroids had the next highest S/N value at 9.76 with the human
Kanslets with the lowest S/N value of 7.34.
The Z' value not only characterizes the robustness of the response to
the compound, it also evaluates the quality of the assay itself (Zhang et
al., 1999). A Z' value between 0.5 and 1 is considered an excellent assay,
with values near or at 1 classiﬁed as an ideal assay (Zhang et al., 1999).
The human Kanslets failed to demonstrate a Z' value in the excellent or
ideal range for any of the experiments run (Table 1). The 2D cell culture
model had a Z' value in the excellent range in response to caffeine only
(Table 1). In contrast, the 3D β-cell model ranked in the excellent range
for every experiment except when stimulated by glucose and
glybenclamide.
4. Discussion
Conventional cell-based drug screening assays are prone to artifacts
due to the reliance on monolayers of cultured cells that do not mimic
the in vivo situation (Breslin & O'Driscoll, 2013; Xi, Yu, Wang, Xu, &
Abassi, 2008). The greatest advances in the use of 3D culture systems
for HTS has been completed in the cancer ﬁeldwhere the 3D cell culture
system has been shown to be more realistic spatially, with biochemical
and cellular heterogeneity (Leong & Ng, 2014). The results of such stud-
ies have illustrated that different results were obtained when the same
molecules were tested on 2D versus 3D cell culture (Walpita &Wagner,
2014). In fact, a large-scale 3D screen identiﬁed unique anti-cancer com-
pounds compared to the same screen conducted on 2D cell culture
(Howes, Richardson, Finlay, & Vuori, 2014). But even with the more
common use of 3D cancer spheroids for drug screens, the researchers
often already have a target molecule that they are monitoring (Suzuki
et al., 2014). Further, they typically use hydrogels or other scaffolds to
create the 3D tumor model (Loessner, Holzapfel, & Clements, 2014;
Song, Park, & Gerecht, 2014).
In contrast to the cancer ﬁeld, few studies have used HTS methods
and 3D cell culturemodels to identify molecules targeted to β-cell func-
tion or viability (Tran et al., 2014). The lack of such a strategy has been
identiﬁed as a major limitation to identifying new promising drugs for
diabetes care (Akash, Rehman, & Chen, 2013). In fact, even when fresh
islets were used for drug screening, theywere ﬁrst dispersed into single
cells grown in a 2D monolayer (Beck et al., 2013; Walpita et al., 2012).
Our previous publications compared spheroids created from cadaveric
islets to native human islets and the pharmaceutical industry standard
of rodent islets (Ramachandran et al., 2014). The results showed that
reaggregated islet clusters from human islets were superior to intact
human islets as a model system for drug discovery. This was easily
noted by comparing the stimulation index (SI) values. The SI is a widely
used assay to determine the proper function of isolated islets with
values above 3 being considered indicative of highly responsive isletcells (Sakata, Egawa, Sumi, & Unno, 2008). In fact the SI values for the
2D and 3D were both over 4 and were not different from each other,
while the value for the human Kanslets was below 2.
The current study utilized the INS-1 832/13 cells as a screening tool
(Hohmeier et al., 1997, 2000) and compared them to the human
Kanslets. This cell line is based on rodent β-cells, but transfected with
the human pro-insulin gene, resulting in a cell line that consistently re-
sponds to known human insulin secretagogues that act in vivo. This is
the ﬁrst study to show that this cell line could be used in a 3D high-
throughput screen format without scaffolds or hydrogels.
A successful screen should be predictive of the human in vivo condi-
tion. The 3Dβ-cell spheroids responded to the insulin secretion agonists
and inhibitors in the predicted manner. In contrast, the cultured β-cells
in 2D failed to respond to glybenclamide, a common treatment for type
2 diabetes. Interestingly, the human islets failed to demonstrate a re-
sponse to increasing concentrations of glucose. This was a surprising re-
sult, as we had previously shown that the human Kanslet was a highly
viable screening model (Ramachandran et al., 2014). However, that
work was completed in the 96-well format. Moving to the 384-well for-
mat for islet cell testing required modiﬁcations described in the
methods section. While the cultured cells were able to be converted to
automated dispensing and testing, the human islet cells showed high
donor-to-donor and within-donor variability that was magniﬁed in
the 384-well format.
The Z' values calculated for this method did not reach ideal levels,
but were better than many other reportedly successful screens
(Albrecht et al., 2004; Li, Xu, Liu, Christoffersen, & Wang, 2013;
Tammela et al., 2004; Zuck et al., 2004), which reinforces the difﬁculty
in working with human islets or β-cell lines. In this study, the β-cell
spheroids had the greatest percentage of excellent Z' scores. In contrast,
the same cells in 2D had only one response that scored in the excellent
range, and that was in response to caffeine, while freshly dispersed
human islets had Z' scores that never reached the excellent or ideal
benchmark. While the 3D β-cell method did provide improvements
over the other two testing models, there is still optimization that
needs to be completed, as the Z' value for the 3D β-cell spheroids in re-
sponse to glucose was below an acceptable range (0.11), and for
glybenclamide, the value was just below an excellent score. (0.48).
Small alterations in the 3D β-cell spheroid screen may further optimize
of the protocol such as testing on smaller diameter spheroids and in-
creasing the drug exposure time from 60 min.
A high-throughput screeningmethod using a cell culture line, rather
than relying on human donor cells, has many advantages, if it reﬂects
the potential in vivo outcome.We have shownwith a robust glucose re-
sponse and reference drugs, that β-cell spheroids tested in a 384-well
format provide a valid phenotypic screen for new diabetes drugs. The
cost of the 3D screening protocol is not signiﬁcantly different from the
same screen in 2D. In fact, the assays were run using standard protocols
and reagents. Only the plate to produce the 3D spheroids was different
from current industry standards. The procedure could ultimately help to
reduce costs and the high attrition rate currently inherent in ﬁnding and
developing new diabetes drugs (Kimlin, Kassis, & Virador, 2013).
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